TriangleBelantamab Mafodotin (NCT05208307)
Belantamab Mafodotin trial for Plasma Cell Myeloma (NCT05208307). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with specified high-risk myeloma who achieved at least a partial response after an autologous stem-cell transplant. Enrollment occurs 60–100 days after transplant.
The idea: maintenance combines belantamab mafodotin, which delivers a cell-killing drug to BCMA-bearing cells, with oral pomalidomide and dexamethasone. Belantamab is infused every eight weeks; pomalidomide is taken on days 1–21 of each 28-day cycle, with weekly dexamethasone. Researchers assess complete responses and safety.
This phase 2 study plans 34 patients. Ajay Nooka leads at Emory in Atlanta, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.